Biodexa Pharma Induces Warrant Exercise

TL;DR

Biodexa Pharma is sweetening the deal for warrant holders to exercise early, potentially bringing in cash.

AI Summary

On May 22, 2024, Biodexa Pharmaceuticals PLC entered into letter agreements with certain holders of its outstanding warrants to induce them to exercise their warrants. This transaction aims to encourage the early exercise of these warrants.

Why It Matters

This action by Biodexa Pharmaceuticals PLC could lead to an increase in the company's cash position if warrant holders exercise their options, potentially funding future operations or growth initiatives.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a warrant inducement transaction, which is a common corporate action with no immediate negative implications.

Key Players & Entities

• Biodexa Pharmaceuticals PLC (company) — Registrant
• May 22, 2024 (date) — Date of letter agreements

FAQ

Key Financial Figures

• $1.50 — t is being exercised will be reduced to $1.50 per share. Each Holder that exercises i
• $6,500,000 — ceiving gross proceeds of approximately $6,500,000.00, before deducting placement agent fe

Filing Documents

• r5212406k.htm (6-K) — 22KB
• ex4_1.htm (EX-4.1) — 122KB
• ex4_2.htm (EX-4.2) — 122KB
• ex10_1.htm (EX-10.1) — 55KB
• ex99_1.htm (EX-99.1) — 18KB
• 0001214659-24-009731.txt ( ) — 340KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Explanatory Note Warrant Inducement Transaction On May 22, 2024, Biodexa Pharmaceuticals PLC (the “Company”) entered into letter agreements (the “Agreements”) with certain accredited holders (collectively, the “Holders”) of the Company’s outstanding Series E warrants (“Series E Warrants”) and Series F warrants (“Series F Warrants”) issued on December 21, 2023 (collectively, the “Existing Warrants”). Pursuant to the Agreements, the exercise price of each Existing Warrant that is being exercised will be reduced to $1.50 per share. Each Holder that exercises its Existing Warrants pursuant to the Agreement, will receive one (1) replacement warrant for each Series E Warrant exercised (“Series G Warrants”) and one (1) replacement warrant for each Series F Warrant exercised (“Series H Warrants,” and collectively with the Series G Warrant, the “Replacement Warrants”). The Replacement Warrants will be exercisable immediately and expire after five (5) years, for the Series G Warrants, and one (1) year, for the Series H Warrants, from the date of issuance. The Replacement Warrants will be subject to adjustment in the event of stock splits, dividends, subsequent rights offerings, pro rata distributions, and certain fundamental transactions, as more fully described in the Replacement Warrants. The Replacement Warrants contain standard anti-dilution provisions but do not contain any price protection provisions with respect to future securities offerings of the Company. The Holders are collectively exercising an aggregate of 4,358,322 Existing Warrants consisting of: (i) 1,887,087 Series E Warrants and (ii) 2,471,235 Series F Warrants. The Holders are exercising all of their Existing Warrants. As a result of the exercises, the Company will issue an aggregate of 4,358,322 of its American depositary shares (“ADSs”), with each ADS representing 400 of the Company’s ordinary shares, nominal value £0.001 per share (the “Ordinary Shares”). The shares underlying the Existing Warrants have all been registered on a Form S-1 registration statement (File No. 333-274895). The closing is expected to take place on or about May 22, 2024, subject to customary closing conditions. The Company anticipates receiving gross proceeds of approximately $6,500,000.00, before deducting placement agent fees and estimated offering expenses. In the event that the exercise of Existing Warrants would cause the Holder to exceed the beneficial ownership limitation provisions contained in the Existing Warrants, the Company shall only issue such number of shares that would not cause the Holder to exceed the maximum amount permitted thereunder, with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations. The Company agreed to file a resale registration statement registering the shares underlying the Replacement Warrants (“Resale Registration Statement”) within fifteen (15) days after the Agreement, and to use commercially reasonable efforts to cause the Resale Registration Statement to be effective within forty-five (45) days of the initial filing date of the Agreement. of the Agreement, the Company will be required to pay certain liquidated damages if the shares underlying the Replacement Warrants are not registered for resale or in the event that the Company fails to remove the restrictive legend on the shares underlying the Replacement Warrants on a timely basis as more fully described in the Agreement. In the event that the shares underlying the Replacement Warrants are not subject to an effective registration statement at the time of exercise, the Replacement Warrants may be exercised on a cashless basis at any time after six (6) months from the issuance date. In connection with the transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Ladenburg Thalmann & Co., Inc. (the “Placement Agent”) a cash fee e

View Full Filing

View this 6-K filing on SEC EDGAR